University Hospitals Plymouth NHS Trust

Freedom of Information Act Disclosure log - Reply Extract

File reference	W21FOI136
Key words	Treatment for Head & Neck Cancer (squamous cell carcinoma)
Date of release	02/09/2021
Attachments	No

You asked

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?

- **Carboplatin (monotherapy or in combination with 5-FU)** Carboplatin (single agent) = Five or fewer
- **Cisplatin (monotherapy or in combination with 5-FU)** (Cisplatin, Docetaxel & Fluorouracil = Five or fewer
  Cisplatin (Single agent in PATHOS trial) = Five or fewer
- **Cetuximab with/without chemotherapy** = 0
- **Cetuximab with radiotherapy** = 0
- **Pembrolizumab monotherapy** = Five or fewer
- **Pembrolizumab with chemotherapy** = 0
- **Nivolumab** = Five or fewer
- **Docetaxel (monotherapy or in combination with 5-FU)** = 0
- **Fluorouracil (5FU)** = 0
- **Radiotherapy only** = 23 started a new course or RT during this time. Please note we are unable to identify patients that have had only RT so this number will include patients who have had chemoRT or other treatment as well as RT.

Other:

- Capecitabine & carboplatin = Five or fewer
- Capecitabine & cisplatin = Five or fewer
- Carboplatin & Paclitaxel = Five or fewer
- Cemiplimab = Five or fewer
- Cisplatin & RT = 8
- Denosumab = Five or fewer
- Lenvatinib = Five or fewer

We used SACT data 1/3/21 – 31/5/21 and ICD codes C00-C14.8 (lip, oral, pharynx), C30-C32.9 (maxilla and larynx), C41-C41.1 (mandible) and C73-C75.9 (thyroid and adrenal) to identify those patients that have had a cycle prescribed during this time. Please note we are unable to differentiate just those head and neck patients with squamous cell carcinoma so the numbers

are for all head and neck patients who have had a cycle of the following drugs between March 21 – May 21.

2. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer (squamous cell carcinoma)? If so, can you please provide the name of each trial along with the number of patients taking part?

The Trust completes a non-disclosure agreement when it participates in clinical trials because the information is commercially sensitive. The Trust would breach the conditions of any agreement and reveal commercially sensitive information if it were to provide an answer to this question. This would constitute a breach of confidence that would be actionable in court by that or any other person. The Trust is declining to supply the information in compliance with section 41.-(2).

3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?

- Aflibercept = 0
- Bevacizumab = 0
- Capecitabine = 16
- CAPIRI = 12
- CAPOX (XELOX) = 42 (11 OXALICAP and 31 XELOX)
- Cetuximab in combination with FOLFIRI = Five or fewer
- Cetuximab in combination with FOLFOX = 0
- Cetuximab not in combination with FOLFIRI or FOLFOX = See other SACT'
- Irinotecan only = Five or fewer
- FOLFIRI = 6
- FOLFOX = Five or fewer
- Fluorouracil (5FU) only = 0
- Oxaliplatin only = 0
- Panitumumab in combination with FOLFIRI = Five or fewer
- Panitumumab in combination with FOLFOX = Five or fewer
- Panitumumab not in combination with FOLFIRI or FOLFOX = 0
- Nivolumab = Five or fewer
- Raltitrexed = Five or fewer
- Ramucirumab = 0
- Regorafenib = 0
- Sorafenib = 0
- Other SACT:
- Capecitabin & RT = Five or fewer
- Carboplatin & paclitaxel = Five or fewer
- Denosumab = Five or fewer
- Encorafenib & cetuximab = Five or fewer
- FOLFIRINOX = Five or fewer
- Lonsurf = 7
- mFOLFIRINOX = Five or fewer

- Mitomycin C, capecitabin and RT = Five or fewer
- Mitomycin C & capecitabin = Five or fewer
- Pembrolizumab = Five or fewer
- Pemetrexed = Five or fewer
- Somatuline Autogel = Five or fewer
- Sunitinib = Five or fewer
- TOMOX (raltitrexed & oxaliplatin) = Five or fewer

Used SACT data 1/3/21 – 31/5/21 and ICD codes C17-17.9 (small intestine), C18-18.9 (colon), C19 (rectosigmoid), C20 (rectum) and C21-21.8 (anus and anal canal) to identify those patients that have had a cycle prescribed during this time

Legal notes:
University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b), unless otherwise specified below and for that reason

It constitutes personal information.
Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. Figures of five or fewer are considered personally identifiable information. Our approach avoids a breach of the first two Data Protection Act principles and the general right to object to processing, whilst providing you with as much detail as possible. This is in accordance with section 40.-(2)(a) and (b) by virtue of the first and second condition.

The information is or would be provided in confidence as part of a non-disclosure agreement because it or would be commercially sensitive.

Section 41 can apply if

- it was obtained by the authority from any other person,
- its disclosure would constitute a breach of confidence.
- a legal person could bring a court action for that breach of confidence, and
- that court action would be likely to succeed

Section 41(2) provides an exclusion from the duty to confirm or deny whether information is held. This exclusion applies if confirming or denying that information is held would in itself give rise to a breach of confidence, actionable by any person, that would be likely to succeed.

Section 43 the commercial Interest exemption has not been applied because we are relying on section 41 however at review any review should consider the use of section 43(2 and 3)

Attachments included: No

University Hospitals Plymouth
NHS Trust